Adaptimmune Therapeutics (ADAP) announced on Monday that it entered into a new strategic five-year strategic manufacturing agreement with PCT, a subsidiary of Caladrius Biosciences (NASDAQ: CLBS) for the supply of ADAP�s SPEAR T-cell therapies. According to the agreement, Adaptimmune will gain access to an EU and FDA compliant manufacturing unit at PCT along with highly committed staff.